Which has preferable earnings & valuation, CPH or THCX?

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cipher Pharmaceuticals C$49.62M 7.22 C$11.41M C$1.12 12.59 Hydropothecary N/A N/A N/A N/A N/A

Do analysts recommend CMED or CPH?

Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 20.57%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than CanniMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CanniMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cipher Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, CMED or CPH?

Cipher Pharmaceuticals has higher revenue and earnings than CanniMed Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CanniMed Therapeutics N/A N/A N/A N/A N/A Cipher Pharmaceuticals C$49.62M 7.22 C$11.41M C$1.12 12.59

Cipher Pharmaceuticals (CPH) Competitors

C$14.10 -0.22 (-1.54%)

As of 08/21/2026 04:00 PM Eastern

Compare

CPH vs. DHT.UN, THCX, GUD, TLRY, and CMED

Should you buy Cipher Pharmaceuticals stock or one of its competitors? Cipher Pharmaceuticals's main competitors and comparable companies include DRI Healthcare Trust (DHT.UN), Hydropothecary (THCX), Knight Therapeutics (GUD), Tilray Brands (TLRY), and CanniMed Therapeutics (CMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Cipher Pharmaceuticals (TSE:CPH) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

In the previous week, Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled DRI Healthcare Trust'saverage media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
DRI Healthcare Trust	Neutral

Cipher Pharmaceuticals presently has a consensus target price of C$17.00, suggesting a potential upside of 20.57%. DRI Healthcare Trust has a consensus target price of C$25.20, suggesting a potential upside of 41.57%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, analysts plainly believe DRI Healthcare Trust is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Cipher Pharmaceuticals has a beta of 1.153789, suggesting that its share price is 15% more volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.350693, suggesting that its share price is 65% less volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 58.81% compared to DRI Healthcare Trust's net margin of 5.02%. Cipher Pharmaceuticals' return on equity of 22.74% beat DRI Healthcare Trust's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	58.81%	22.74%	7.90%
DRI Healthcare Trust	5.02%	2.06%	4.22%

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.8% of DRI Healthcare Trust shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cipher Pharmaceuticals has higher earnings, but lower revenue than DRI Healthcare Trust. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$49.62M	7.22	C$11.41M	C$1.12	12.59
DRI Healthcare Trust	C$172.34M	5.68	C$9.73M	-C$0.80	N/A

Summary

Cipher Pharmaceuticals beats DRI Healthcare Trust on 10 of the 15 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Hydropothecary?

Cipher Pharmaceuticals (TSE:CPH) and Hydropothecary (CVE:THCX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, suggesting a potential upside of 20.57%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cipher Pharmaceuticals is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Hydropothecary'saverage media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
Hydropothecary	Neutral

Cipher Pharmaceuticals has a net margin of 58.81% compared to Hydropothecary's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 22.74% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	58.81%	22.74%	7.90%
Hydropothecary	N/A	N/A	N/A

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$49.62M	7.22	C$11.41M	C$1.12	12.59
Hydropothecary	N/A	N/A	N/A	N/A	N/A

Summary

Cipher Pharmaceuticals beats Hydropothecary on 8 of the 8 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Cipher Pharmaceuticals	Neutral

22.8% of Knight Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cipher Pharmaceuticals has lower revenue, but higher earnings than Knight Therapeutics. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$547.31M	1.73	-C$30.73M	C$0.15	64.40
Cipher Pharmaceuticals	C$49.62M	7.22	C$11.41M	C$1.12	12.59

Cipher Pharmaceuticals has a net margin of 58.81% compared to Knight Therapeutics' net margin of 2.72%. Cipher Pharmaceuticals' return on equity of 22.74% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	2.72%	1.91%	0.51%
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

Knight Therapeutics has a beta of -0.194384, indicating that its stock price is 119% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.153789, indicating that its stock price is 15% more volatile than the broader market.

Knight Therapeutics presently has a consensus price target of C$9.50, suggesting a potential downside of 1.66%. Cipher Pharmaceuticals has a consensus price target of C$17.00, suggesting a potential upside of 20.57%. Given Cipher Pharmaceuticals' higher possible upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cipher Pharmaceuticals beats Knight Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Tilray Brands has a beta of 2.949831, suggesting that its share price is 195% more volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.153789, suggesting that its share price is 15% more volatile than the broader market.

4.2% of Tilray Brands shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 0.7% of Tilray Brands shares are owned by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cipher Pharmaceuticals has a net margin of 58.81% compared to Tilray Brands' net margin of -15.22%. Cipher Pharmaceuticals' return on equity of 22.74% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-15.22%	-8.85%	-1.41%
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

Cipher Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$915.45M	1.00	-C$183.24M	-C$1.09	N/A
Cipher Pharmaceuticals	C$49.62M	7.22	C$11.41M	C$1.12	12.59

Tilray Brands currently has a consensus price target of C$13.30, indicating a potential upside of 99.40%. Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 20.57%. Given Tilray Brands' higher possible upside, research analysts clearly believe Tilray Brands is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Tilray Brands had 4 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 4 mentions for Tilray Brands and 0 mentions for Cipher Pharmaceuticals. Tilray Brands' average media sentiment score of 0.26 beat Cipher Pharmaceuticals' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Tilray Brands	Neutral
Cipher Pharmaceuticals	Neutral

Summary

Cipher Pharmaceuticals beats Tilray Brands on 8 of the 14 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to CanniMed Therapeutics?

CanniMed Therapeutics (TSE:CMED) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Cipher Pharmaceuticals has higher revenue and earnings than CanniMed Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A
Cipher Pharmaceuticals	C$49.62M	7.22	C$11.41M	C$1.12	12.59

In the previous week, CanniMed Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CanniMed Therapeutics	Neutral
Cipher Pharmaceuticals	Neutral

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 20.57%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than CanniMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CanniMed Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cipher Pharmaceuticals has a net margin of 58.81% compared to CanniMed Therapeutics' net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 22.74% beat CanniMed Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CanniMed Therapeutics	N/A	N/A	N/A
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

Summary

Cipher Pharmaceuticals beats CanniMed Therapeutics on 8 of the 8 factors compared between the two stocks.

Get Cipher Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPH vs. The Competition

Export

Metric	Cipher Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$358.35M	C$12.57B	C$7.37B	C$12.56B
Dividend Yield	N/A	2.61%	2.53%	6.21%
P/E Ratio	12.59	789.80	272.60	39.07
Price / Sales	7.22	764.50	618.96	10.02
Price / Cash	3.53	96.77	78.62	82.29
Price / Book	2.61	11.89	13.05	4.79
Net Income	C$11.41M	C$2.81B	C$3.47B	C$299.09M
7 Day Performance	-0.28%	1.77%	2.09%	0.82%
1 Month Performance	-14.23%	3.85%	6.64%	5.39%
1 Year Performance	-6.62%	6.56%	25.02%	35.05%

Cipher Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPH Cipher Pharmaceuticals	N/A	C$14.10 -1.5%	C$17.00 +20.6%	-6.6%	C$358.35M	C$49.62M	12.59	5
DHT.UN DRI Healthcare Trust	N/A	C$18.23 -1.0%	C$25.20 +38.2%	+24.8%	C$1.00B	C$172.34M	N/A	N/A	Positive News
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume
GUD Knight Therapeutics	N/A	C$9.21 -0.9%	C$9.50 +3.1%	+49.8%	C$904.72M	C$547.31M	61.40	725	Positive News
TLRY Tilray Brands	1.6466 of 5 stars	C$6.55 +0.2%	C$13.30 +103.1%	-58.1%	C$892.14M	C$915.45M	N/A	2,650	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:CPH) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. DHT.UN, THCX, GUD, TLRY, and CMED

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Summary

How does Cipher Pharmaceuticals compare to CanniMed Therapeutics?

Summary

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. DHT.UN, THCX, GUD, TLRY, and CMED

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Does the media favor CPH or DHT.UN?

Do analysts recommend CPH or DHT.UN?

Which has more volatility & risk, CPH or DHT.UN?

Is CPH or DHT.UN more profitable?

Do insiders and institutionals have more ownership in CPH or DHT.UN?

Which has higher earnings & valuation, CPH or DHT.UN?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Do analysts recommend CPH or THCX?

Do insiders and institutionals hold more shares of CPH or THCX?

Does the media refer more to CPH or THCX?

Is CPH or THCX more profitable?

Which has preferable earnings & valuation, CPH or THCX?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Does the media favor GUD or CPH?

Do institutionals and insiders hold more shares of GUD or CPH?

Which has higher valuation & earnings, GUD or CPH?

Is GUD or CPH more profitable?

Which has more volatility & risk, GUD or CPH?

Do analysts rate GUD or CPH?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Which has more risk and volatility, TLRY or CPH?

Do insiders & institutionals have more ownership in TLRY or CPH?

Is TLRY or CPH more profitable?

Which has higher valuation & earnings, TLRY or CPH?

Do analysts prefer TLRY or CPH?

Does the media favor TLRY or CPH?

Summary

How does Cipher Pharmaceuticals compare to CanniMed Therapeutics?

Which has preferable earnings & valuation, CMED or CPH?

Does the media prefer CMED or CPH?

Do insiders and institutionals believe in CMED or CPH?

Do analysts recommend CMED or CPH?

Is CMED or CPH more profitable?

Summary

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools